Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF) has now invented a new technology that it says will be a valuable tool for cannabinoid producers around the globe.
On Tuesday, the Australian medical cannabinoid company announced the launch of ZYRAYDI, a proprietary enhanced distillate capture and dissolution matrix (EDCDM) technology.
The company claims that ZYRAYDI enables it to trap distillate in a so-called “free flow powder matrix” therefore enabling increased rates of dissolution in the body.
The company says that using ZYRAYDI will only require minimal capital expenditure on raw materials and equipment and that it can easily adapt to any pre-existing capsule and tablet program from other companies.
Zelira says that the matrix for the new technology consists of pharmaceutical grade excipients that are approved by the FDA and can be altered to cater to vegan, allergen free, non-GMO and other requirements depending on who chooses to utilize it.
“ZYRAYDI solves two key issues holding back wider acceptance of cannabinoid medicinal products – the difficulty in formulating solid oral dosage drugs with distillate, and the low rate of dissolution in the body from capsules and tablets,” said Oludare Odumosu, CEO of Zelira Therapeutics.
“We strongly believe that the cannabinoid-based medicine market will scale up significantly when the ability to consistently formulate, validate and commercialize dosage forms that closely resemble current pharmaceutical drugs becomes available,” added Odumosu in relation to the potential of ZYRAYDI.